WonderTx

Extrapolative AI to unlock First-in-Class drugs

Based based in San Francisco, CA, USA; Remote, WonderTx works in healthcare.

Profile

We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery.  This should dramatically increase our probability of success.

There’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.

Within the healthcare space, the company focuses on its core offering rather than a broad product line.

The company is recorded as being based in San Francisco, CA, USA; Remote.

Directory data places it at the Summer 2026 stage.

Recorded headcount: 3 employees.

Website: wondertx.ai